Aetna (NYSE:AET) is implementing a comprehensive plan to increase the quality of genetic diagnosis and treatment of breast cancer. The company is guiding members and physicians to laboratories that meet national guidelines for genetic testing accuracy. Aetna also is funding research to understand the use of genetic tests in breast cancer treatment. (more…)
In trying to find out why HER2-positive breast cancer can be more aggressive than other forms of the disease, UC Davis Cancer Center researchers have surprisingly discovered that HER2 itself is the culprit. By shutting down its own regulator gene, HER2 creates a permissive environment for tumor growth. (more…)
Audrey Birt, Breakthrough Breast Cancer’s Director for Scotland says: “Breakthrough Breast Cancer welcomes the publication today of Better Cancer Care. It’s now essential that clear plans are put in place to ensure the recommendations in this report are implemented as soon as possible. In order to translate this into real benefits it is also essential that patients are involved in the development of cancer services. (more…)
Dune Medical Devices, Ltd. today announced the launch of a pivotal clinical trial of the MarginProbe? intraoperative, real-time, positive margin detection system, following U.S. Food and Drug Administration (FDA) investigational device exemption (IDE) approval of its protocol during breast cancer surgery. With the FDA IDE approval in place, Dune is launching a nationwide U.S. (more…)